A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)

This is a open label mutli-center open-label study to provide continued supply of itacitinib to participants from Incyte-sponsored studies of itacitinib INCB39110-209 and INCB39110-230. Eligible participants will receive treatment with itacitinib as per the treatment dose and schedule they received in the study in which they were originally enrolled. This is referred to as the parent protocol. Participants who receive itacitinib in this study may continue treatment as long as the regimen is tolerated, the participant is deriving clinical benefit (in the opinion of the investigator), and the participant does not meet discontinuation criteria.

A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

Recruitment

Summary

Participation Requirements

Description

Tracking Information